 Both C5a and C5b-9 cause the complement-mediated events that are characteristic of PNH and aHUS.The metabolism of eculizumab is thought to occur via lysosomal enzymes that cleave the antibody to generate small peptides and amino acids.The volume of distribution of eculizumab in humans approximates that of plasma.